We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+33.31%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.33B
AUM Growth
+$318M
Cap. Flow
-$111M
Cap. Flow %
-4.75%
Top 10 Hldgs %
67.66%
Holding
50
New
8
Increased
6
Reduced
18
Closed
5

Top Buys

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$110M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$95M
3
ALGS icon
Aligos Therapeutics
ALGS
+$50.9M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$37.2M
5
EAR
Eargo, Inc. Common Stock
EAR
+$31M

Top Sells

Rank Stock Value
1
VTI icon
Vanguard Morningstar Total Stock Market ETF
VTI
+$208M
2
MDT icon
Medtronic
MDT
+$103M
3
CTLT
CATALENT, INC.
CTLT
+$60.9M
4
AAPL icon
Apple
AAPL
+$25.8M
5
SIBN icon
SI-BONE Inc
SIBN
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 65.57%
2 Technology 5.9%
3 Financials 5.43%
4 Communication Services 5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
$376M 16.14%
1,933,900
-1,136,500
-37% -$208M
NKTX icon
2
Nkarta
NKTX
$152M
$172M 7.36%
2,793,864
– –
INGN icon
3
Inogen
INGN
$174M
$159M 6.8%
3,549,320
– –
AAPL icon
4
Apple
AAPL
$4.97T
$138M 5.9%
1,037,404
-214,700
-17% -$25.8M
PRAX icon
5
Praxis Precision Medicines
PRAX
$8.11B
$134M 5.76%
+162,805
New +$95M
HRMY icon
6
Harmony Biosciences
HRMY
$2.08B
$131M 5.61%
3,622,471
-132,502
-4% -$5.35M
BN icon
7
Brookfield
BN
$102B
$127M 5.43%
5,738,048
– –
SPRB
8
Spruce Biosciences
SPRB
$114M
$121M 5.2%
+66,524
New +$110M
CABO icon
9
Cable One
CABO
$237M
$117M 5%
52,341
-4,950
-9% -$9.79M
CTLT
10
DELISTED
CATALENT, INC.
CTLT
$104M 4.45%
997,349
-628,651
-39% -$60.9M
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$88.8M 3.81%
2,645,446
– –
ALGS icon
12
Aligos Therapeutics
ALGS
$26.3M
$72.3M 3.1%
+104,583
New +$50.9M
INZY
13
DELISTED
Inozyme Pharma
INZY
$53M 2.27%
2,569,379
– –
FRLN
14
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$43.1M 1.85%
157,415
+113,082
+255% +$28.4M
MIRM icon
15
Mirum Pharmaceuticals
MIRM
$6.56B
$42.7M 1.83%
2,445,147
– –
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$38.9M 1.67%
1,684,795
-635,231
-27% -$13M
EAR
17
DELISTED
Eargo, Inc. Common Stock
EAR
$33M 1.42%
+36,854
New +$31M
CMPI
18
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$31.7M 1.36%
2,170,100
– –
DMRA
19
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.74B
$31.2M 1.34%
+99,912
New +$37.2M
GRTX
20
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$30.3M 1.3%
2,959,021
-450,000
-13% -$4.92M
SPNE
21
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$23.4M 1%
1,339,085
-338,407
-20% -$5.15M
BPMC
22
DELISTED
Blueprint Medicines
BPMC
$22.1M 0.95%
197,000
-37,979
-16% -$4M
VRNA
23
DELISTED
Verona Pharma
VRNA
$18.3M 0.78%
2,608,755
+808,008
+45% +$5.46M
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.04B
$17.8M 0.76%
384,117
-821
-0.2% -$32.6K
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.55B
$17.5M 0.75%
867,724
+73,355
+9% +$1.58M
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q4 2020 Portfolio in Review

As of Q4 2020, Novo Holdings A/S held 50 positions worth $2.33B, up 16% from $2.01B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Novo Holdings A/S withdrew a net $111M in Q4 2020, closing 5 positions and reducing 18 holdings. Its most notable exit was Medtronic, an estimated $103M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 54% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Spruce Biosciences worth $121M.

  • Novo Holdings A/S's largest Q4 2020 buy was Spruce Biosciences: 66,524 shares worth $121M.
  • Novo Holdings A/S added most to Freeline Therapeutics Holdings plc American Depositary Shares in Q4 2020, an estimated $28.4M increase.
  • Novo Holdings A/S's biggest Q4 2020 reduction was Vanguard Morningstar Total Stock Market ETF, cutting an estimated $208M.
  • Novo Holdings A/S fully exited Medtronic in Q4 2020, selling an estimated $103M.
  • Novo Holdings A/S's ten largest holdings make up 68% of its $2.33B portfolio in Q4 2020.
  • Novo Holdings A/S opened 8 new positions and closed 5 in Q4 2020.
  • Novo Holdings A/S's portfolio value rose 16% quarter-over-quarter to $2.33B.

Based on Novo Holdings A/S's 13F filing for Q4 2020, filed 16 Feb 2021.